SCHEMBL24933817

SCHEMBL24933817

CC(C)CS(=O)(=O)N1CCCOC(COc2ccc(-c3cc(C(N)=O)c(=O)[nH]c3C(F)(F)F)cc2)C1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 4/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
MAPT P10636 2/20 0.34
MAPK1 P28482 2/20 0.34
LIPE Q05469 2/20 0.34
ACLY P53396 1/20 0.33
ALDH1A1 P00352 2/20 0.33
EPHX2 P34913 1/20 0.33
SYK P43405 1/20 0.32
DRD4 P21917 1/20 0.32
PRKAB2 O43741 1/20 0.32
PRKAG1 P54619 1/20 0.32
PRKAA2 P54646 1/20 0.32
PRKAA1 Q13131 1/20 0.32
PRKAG3 Q9UGI9 1/20 0.32
PRKAG2 Q9UGJ0 1/20 0.32
PRKAB1 Q9Y478 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
MITF O75030 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29203334 0.91 LMNA (0.36) IRAK4SMN1; SMN2MAPTMAPK1ACLY
SCHEMBL24933738 0.87 ACLY (0.38) IRAK4ACLYEPHX2PRKAB2PRKAG1
SCHEMBL24932963 0.84 PDK1 (0.34) IRAK4EPHX2SYKDRD4PRKAB2
SCHEMBL24933818 0.83 IRAK4 (0.34) IRAK4EPHX2SYKDRD4PRKAB2
SCHEMBL24933739 0.82 IRAK4 (0.36) IRAK4EPHX2DRD4PRKAB2PRKAG1
SCHEMBL24933571 0.82 HRH3 (0.37) DRD4PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL24933835 0.82 PDK1 (0.40) IRAK4EPHX2DRD4PRKAB2PRKAG1
SCHEMBL24933581 0.81 PRKAB2 (0.43) IRAK4SMN1; SMN2MAPTPRKAB2PRKAG1
SCHEMBL24933840 0.81 PRKAB2 (0.46) SMN1; SMN2MAPTPRKAB2PRKAG1PRKAA2
SCHEMBL24933560 0.80 P2RX3 (0.41) DRD4P2RX3P2RX2FFAR1HRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO claimed
EP-4373809-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS Novartis AG (CH) 2024-05-29 EP disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed
WO-2023002443-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2023-01-26 WO disclosed